KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this setting, dasatinib also increases the percentage of NKG2A−CD57+ NK cells and the expression of activating receptors CD226 (DNAM-1), NKp46 and NKG2D [41], promoting their capacity to kill by degranulation of the CML cell line K562, not expressing HLA class I. Finally, dasatinib-mediated reduction of NKG2A also may boost NK cytotoxicity and improve MMR [18,42].